Two years into the COVID-19 pandemic, engaging with healthcare professionals about treatments has never been more difficult. Consultants, doctors, and nurses are overworked, stressed, and tired.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh